Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award

Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award

CLEVELAND, OH / ACCESSWIRE / March 15, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, announced that Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist for the Company, received the prestigious Golden Axon Award at the World Brain Mapping Foundation (WBMF) Annual Congress, held on February 17, 2023, in Los Angeles, CA.

The Golden Axon Award is presented to individuals connected with the medical community who inspire with goodwill and an enthusiastic interest in science, technology and medicine. Named for the neuron cell fiber that carries outgoing messages to other target cells, the founding principle of the Axon Award is to recognize a highly regarded individual in the public sector who helps raise awareness and funding of WBMF and its mission in the community via fundraising event(s) and activities. For additional information on the event and awards, please visit https://www.worldbrainmapping.org/Annual-Awards-Gala/.

The World Brain Mapping Foundation's Annual Congress event -- "Gathering for Cure" Black Tie Gala -- is designed to recognize pioneers in brain mapping, health policy, neuroscience, and mental health philanthropy, amongst others, while connecting to its mission and bringing its message of neurotech innovation and innovation to the masses. The event also recognizes students, young investigators, and leaders in the field of brain mapping and therapeutics who have made significant contributions as trailblazers. Gala participants include major philanthropists, celebrities, NHL/NBA/MLS/NHF, leading scientists, physicians, neurosurgeons, and neurotechnology.

At the annual congress, Dr. Wheeler and NovAccess CEO Dr. Dwain Irvin presented on immune targets and therapies for malignant brain tumors and disorders. This specifically impacts how NovAccess is currently developing vaccine immunotherapy for malignant brain tumors, as well as targets for its future improvement.

About The World Brain Mapping Foundation and The Society for Brain Mapping and Therapeutics (SBMT)

The World Brain Mapping Foundation focuses on helping wounded soldiers, brain and spine cancers, neurodegenerative disorders (Parkinson's, Alzheimer's, ALS, MS, etc.), and neuropsychiatric and spine disorders. The event includes exciting entertainment and networking with celebrities and world-renowned figures. You will enjoy an excellent ambiance and fine cuisine in a great evening of celebration full of leisure while impacting the mission of a tremendous non-profit.

This Gala fundraiser focuses on mental health and brain and spine disorders. The funding will go to Pioneering initiatives, such as global neuroscience20, women in neuroscience group (WIN), BTIP, Fellowship programs, humanitarian missions as part of international physicians and scientists GPS (UKRAINE), and annual conventions and courses. Hands-on specialized training (BioSkills labs), continued medical education training and certification (CME), and funding for pioneering MedTech, neurotech and neuro pharma tech emerge from the SBMT convention.

The Society for Brain Mapping and Therapeutics (SBMT) is a non-profit society organized for the purpose of encouraging basic and clinical scientists who are interested in areas of Brain Mapping, engineering, stem cell, nanotechnology, imaging and medical device to improve the diagnosis, treatment and rehabilitation of patients afflicted with neurological disorders.

This society promotes the public welfare and improves patient care through the translation of new technologies/therapies into life-saving diagnostic and therapeutic procedures. The society is committed to excellence in education, and scientific discovery. The society achieves its mission through multi-disciplinary collaborations with government agencies, patient advocacy groups, educational institutes and industry as well as philanthropic organization.

Since its inception in 2010, The World Orphan Drug Congress has solidified its position as the largest rare disease and orphan drug conference, globally. Over 3 days, participants will have the opportunity to hear from 300+ speakers across our 16 themes of content, engage in networking opportunities and customize their experience at the congress. For additional information, please go to: https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm.

For additional information, please visit: https://www.worldbrainmapping.org/About/SBMT-History.

About Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc.

Dr. Wheeler has over 30 years of immunology and neurology research experience. His leadership experience is highlighted by his position and previous roles at Cedars-Sinai Medical Center Department of Neurosurgery. Dr. Wheeler was a Professor in the Department for over 20 years, and also served as The Operations Director of Vaccine Manufacturing Laboratory (1997-2018), as part of the Precision Medicine Initiative for Brain Tumors Department of Neurosurgery, Chair of the Institutional Animal Care and Use Committee (IACUC, 2006-2012), and Glioma Immunotherapy Core Director (2003-2018).

In 2023, Dr. Wheeler was appointed as a visiting scientist at UC Santa Cruz, Department of Chemistry & Biochemistry. The UC Santa Cruz Division of Physical & Biological Sciences is a world-leading public research institution with a reputation for instigating some of humanity's most high-impact discoveries and empowering students with immersive research experiences since 1965. It is part of the University of California, and maintains a mission to serve society through "transmitting advanced knowledge, discovering new knowledge, and functioning as an active working repository of organized knowledge" in the physical & biological sciences.

Dr. Wheeler's research has been highlighted by publications in numerous high impact, paradigm shifting manuscripts and several patents. As part of his career achievements, he has executed scientific aspects of commercialization, validation, funding, and marketing for the development of Alzheimer's Disease (AD) biomarker technology.

About NovAccess Global

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our Company has a novel immunotherapeutic approach to treating brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. It is a meaningful technology that could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.

Follow us on social media and stay up to date on all of our developments:

https://www.youtube.com/@novaccess

https://www.facebook.com/novaccessglobal

https://www.linkedin.com/company/64892686

https://twitter.com/novaccessglobal

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

This press release and the interviews to be published as part of the NovAccess Global fireside chat series are for informational purposes only and should not be considered investment advice, an offer to sell, or a solicitation of an offer to buy any security. Interview participants have agreed to participate in this event series and no compensation will be paid or furnished to them or their respective organizations. Participation does not represent an offer to buy or sell any security to or from any person or other entity through their platforms. Prior to making any investment or subscribing to any of the platforms that may be associated with the fireside chat series and re-distribution of related content, listeners/viewers are encouraged to consult with professional financial, legal advisor and tax advisors to assist in due diligence as may be appropriate in determining the risk associated with any investment.

Investor Relations Contact:

Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com

SOURCE: NovAccess Global Inc.